FOSTER CITY — Gilead Sciences Inc. announced plans to launch generic versions of its hepatitis C drugs in the United States, at a time when regulators are looking to lower healthcare costs. The drugmaker’s generic version of drugs such as harvoni and epclusa, which raked in combined sales of $831 million in the quarter ended
PISCATAWAY, N.J. — Hetero Drugs, the India-based parent company of Camber Pharmaceuticals, has been honored by Gilead Sciences its commitment to providing access to life-saving medications for chronic hepatitis C patients around the world. Camber said Wednesday that the award from Gilead — a leader in the development of hepatitis C drugs — recognizes Hetero’s
WOONSOCKET, R.I. — CVS Health and Gilead Sciences have reached a deal to make Gilead’s hepatitis C drugs, Harvoni and Sovaldi, the exclusive option for patients on its commercial drug list, as well as for those it manages on health care exchanges, Medicare Part D and Medicaid. The move partly counteracts a recent decision by
